All lobbying filings

CGCN GROUP, LLC

CGCN GROUP, LLC filed a Q4 report for FRESENIUS KABI USA, LLC on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for FRESENIUS KABI USA, LLC · Healthcare company

All filings by CGCN GROUP, LLC · Everything FRESENIUS KABI USA, LLC has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Illinois

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Manufacturing

Buy America legislation, tariffs, and tax incentives.

Tariff (miscellaneous tariff bills)

Section 232 investigation into pharmaceuticals and unfair trade practices.

Taxation/Internal Revenue Code

U.S. manufacturing incentives.

Trade (domestic/foreign)

Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.